DNLI Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

20.170

Open

19.600

VWAP

19.00

Vol

3.00M

Mkt Cap

2.95B

Low

18.230

Amount

57.00M

EV/EBITDA(TTM)

Total Shares

158.68M

2.32B

EV/OCF(TTM)

P/S(TTM)

Denali Therapeutics Inc. is a biopharmaceutical company establishing a new class of biotherapeutics designed to cross the blood-brain barrier using its TransportVehicle platform. It is focused on building a portfolio of therapeutic candidates by investing in its TV franchises, i.e., Enzyme TV (ETV), Oligonucleotide TV (OTV), and Antibody TV (ATV), to advance programs for rare diseases, such as lysosomal storage diseases, and common diseases, such as Alzheimer's disease and Parkinson's disease. Its most advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (Hunter syndrome). TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for mucopolysaccharidosis IIIA (Sanfilippo syndrome type A), DNL593 (PTV:PGRN) for frontotemporal dementia-granulin, DNL628 (OTV:MAPT) for Alzheimer’s disease, and DNL952 (ETV:GAA) for Pompe disease. It is also pursuing opportunities in other disease areas including oncology.

Events Timeline

(ET)

2026-04-05

21:20:00

Denali Therapeutics Regains Full Control of DNL593

News

8.5

04-20Globenewswire

Transformation of Value in Biotechnology Sector

8.5

04-20Newsfilter

Biotechnology Sector Undergoes Value Transformation

8.5

04-06NASDAQ.COM

Denali Regains Full Rights to DNL593 Therapy

9.0

04-03Newsfilter

Denali Continues Clinical Development of DNL593 After Takeda Collaboration Termination

7.5

04-03moomoo

Takeda Ends Collaboration Agreement with Denali Therapeutics on DNL593

8.5

04-01Newsfilter

Avaí Bio Initiates Master Cell Bank Manufacturing

10 Analyst Rating

Wall Street analysts forecast DNLI stock price to rise

10 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

25.00

Averages

32.78

High

40.00

Current: 0.000

Low

25.00

Averages

32.78

High

40.00

Baird

Outperform

maintain

$32 -> $34

AI Analysis

2026-04-07

Reason

Baird

Price Target

$32 -> $34

AI Analysis

2026-04-07

maintain

Outperform

Reason

Baird raised the firm's price target on Denali Therapeutics to $34 from $32 and keeps an Outperform rating on the shares. The firm updated its model following the return of DNL-593 from Takeda Pharmaceuticals giving them full control of the FTD-GRN program.

BTIG

Buy

maintain

$38 -> $39

2026-04-06

Reason

BTIG

Price Target

$38 -> $39

2026-04-06

maintain

Buy

Reason

BTIG raised the firm's price target on Denali Therapeutics to $39 from $38 and keeps a Buy rating on the shares as the company regains full rights to investigational therapy DNL593 for GRN-related Frontotemporal Dementia. Noting a "promising" program is back, the firm says it is "curious as prior failure very modestly related," but notes some caution seems appropriate. With that said, BTIG believes the bigger total addressable market supports raising the price target despite the added risk.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for DNLI

Unlock Now

Valuation Metrics

The current forward P/E ratio for Denali Therapeutics Inc (DNLI.O) is 0.00, compared to its 5-year average forward P/E of -11.78. For a more detailed relative valuation and DCF analysis to assess Denali Therapeutics Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-11.78

Current PE

0.00

Overvalued PE

-3.64

Undervalued PE

-19.92

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-8.87

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

-1.49

Undervalued EV/EBITDA

-16.25

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

68.65

Current PS

28.93

Overvalued PS

118.44

Undervalued PS

18.87

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

best stock for swing traders tomorrow

Intellectia · 75 candidates

Price: $5.00 - $100.00Rsi Category: moderateList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceCrossAboveMA20One Day Rise Prob: >= 60Monthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

DNLI

Denali Therapeutics Inc

3.15B

MITK

Mitek Systems Inc

647.57M

SXC

SunCoke Energy Inc

552.33M

RDWR

Radware Ltd

1.10B

DHT

DHT Holdings Inc

2.91B

PHVS

Pharvaris NV

1.87B

suitable for swing trade?

Intellectia · 31 candidates

Region: USVolume: >= 3,000,000Rsi Category: moderateBeta: HighRiskList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA200Month Price Change Pct: $-15.00 - $-3.00

Ticker

Name

Market Cap$

ALLO

Allogene Therapeutics Inc

550.94M

RKLB

Rocket Lab Corp

34.69B

DNLI

Denali Therapeutics Inc

2.88B

Micron Technology Inc

402.85B

NNDM

Nano Dimension Ltd

355.47M

CIFR

Cipher Digital Inc

5.57B

best option put tickers for rest of day

Intellectia · 1032 candidates

Volume: >= 200,000Price Change Pct: <= $-1.00List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceBelowMA20Is Optionable: True

Ticker

Name

Market Cap$

CMBM

Cambium Networks Corp

49.99M

TASK

Taskus Inc

949.08M

DERM

Journey Medical Corp

227.14M

CBUS

Cibus Inc

198.59M

MLKN

MillerKnoll Inc

1.32B

DYAI

Dyadic International Inc

31.57M

show me stock that are going to Gap down

Intellectia · 31 candidates

Market Cap: >= 300.00MRegion: USPrice: >= $3.00List Exchange: XNYS, XNAS, XASEGap Pattern: GapDownMonthly Average Dollar Volume: >= 300,000

Ticker

Name

Market Cap$

DNLI

Denali Therapeutics Inc

3.56B

RMBS

Rambus Inc

10.38B

SFIX

Stitch Fix Inc

468.27M

RLMD

Relmada Therapeutics Inc

698.57M

ASTL

Algoma Steel Group Inc

436.52M

HSY

Hershey Co

43.98B

any good trades for today

Intellectia · 40 candidates

Price: $5.00 - $100.00Volume: >= 1,000,000Price Change Pct: $3.00 - $15.00Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20

Ticker

Name

Market Cap$

DYN

Dyne Therapeutics Inc

2.45B

AXTI

AXT Inc

1.79B

SLDB

Solid Biosciences Inc

525.89M

CAPR

Capricor Therapeutics Inc

1.52B

ICL

ICL Group Ltd

6.38B

TALK

Talkspace Inc

788.52M

Strongest buys

Intellectia · 54 candidates

Market Cap: >= 2.00BAnalyst Consensus: Strong BuyList Exchange: XNYS, XNAS, XASETarget Price Upside Potential: MoreAbovePriceMoving Average Relationship: PriceAboveMA200Monthly Average Dollar Volume: >= 500,000

Ticker

Name

Market Cap$

HSAI

Hesai Group

3.73B

RIOT

Riot Platforms Inc

5.75B

SYRE

Spyre Therapeutics Inc

2.48B

IMVT

Immunovant Inc

5.24B

EWTX

Edgewise Therapeutics Inc

2.98B

NUVL

Nuvalent Inc

7.99B

Exploding stocks

Intellectia · 10 candidates

Market Cap: >= 1000.00MRelative Vol: >= 1.50Beta: HighRiskWeek Price Change Pct: >= $5.00Month Price Change Pct: >= $20.00Monthly Average Dollar Volume: >= 500,000

Ticker

Name

Market Cap$

STX

Seagate Technology Holdings PLC

88.88B

ALGM

Allegro Microsystems Inc

6.83B

DNLI

Denali Therapeutics Inc

3.39B

MOD

Modine Manufacturing Co

9.72B

ACMR

ACM Research Inc

3.77B

MBIN

Merchants Bancorp

1.90B

best strong buy for today

Intellectia · 86 candidates

Analyst Consensus: Strong BuyList Exchange: XNYS, XNAS, XASETarget Price Upside Potential: MoreAbovePriceMoving Average Relationship: PriceAboveMA20One Day Rise Prob: >= 55Monthly Average Dollar Volume: >= 500,000

Ticker

Name

Market Cap$

CING

Cingulate Inc

43.41M

CATX

Perspective Therapeutics Inc

261.77M

ELVN

Enliven Therapeutics Inc

1.51B

ADTN

ADTRAN Holdings Inc

757.90M

UTI

Universal Technical Institute Inc

1.52B

CNTA

Centessa Pharmaceuticals PLC

3.82B

best moving stock right now

Intellectia · 16 candidates

Market Cap: >= 2.00BRegion: USPrice: >= $5.00Volume: >= 2,000,000Price Change Pct: >= $5.00List Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

LBRT

Liberty Energy Inc

3.50B

VIAV

Viavi Solutions Inc

4.74B

LUV

Southwest Airlines Co

21.63B

RCL

Royal Caribbean Cruises Ltd

81.36B

TAL

TAL Education Group

6.55B

ALGM

Allegro Microsystems Inc

6.40B

entonces que acciones?

Intellectia · 74 candidates

Market Cap: >= 3.00BRsi Category: moderateWeek Price Change Pct: $5.00 - $20.00Ema 20: >= -100Ema 60: >= -100Monthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

SSL

Sasol Ltd

4.76B

LMND

Lemonade Inc

6.97B

TEO

Telecom Argentina SA

5.50B

SBS

Companhia de Saneamento Basico do Estado de Sao Paulo - SABESP

18.55B

KEP

Korea Electric Power Corp

27.73B

PKX

Posco Holdings Inc

19.18B

Whales Holding DNLI

Bluebox Asset Management Uk Ltd.

Crestline Investors Inc.

Cercano Management LLC

Baker Bros. Advisors LP

Trading Trends

People Also Watch

Frequently Asked Questions

What is Denali Therapeutics Inc (DNLI) stock price today?

The current price of DNLI is 18.6 USD — it has decreased -7.28

What is Denali Therapeutics Inc (DNLI)'s business?

What is the price predicton of DNLI Stock?

Wall Street analysts forecast DNLI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DNLI is32.78 USD with a low forecast of 25.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Denali Therapeutics Inc (DNLI)'s revenue for the last quarter?

Denali Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased

What is Denali Therapeutics Inc (DNLI)'s earnings per share (EPS) for the last quarter?

Denali Therapeutics Inc. EPS for the last quarter amounts to -0.73 USD, increased 8.96

How many employees does Denali Therapeutics Inc (DNLI). have?

Denali Therapeutics Inc (DNLI) has 503 emplpoyees as of April 30 2026.

What is Denali Therapeutics Inc (DNLI) market cap?

Today DNLI has the market capitalization of 2.95B USD.

DNLI Overview

DNLI Overview

Events Timeline

News

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Related Community Screener

Whales Holding DNLI

Trading Trends

People Also Watch

Frequently Asked Questions

What is Denali Therapeutics Inc (DNLI) stock price today?

What is Denali Therapeutics Inc (DNLI)'s business?

What is the price predicton of DNLI Stock?

What is Denali Therapeutics Inc (DNLI)'s revenue for the last quarter?

What is Denali Therapeutics Inc (DNLI)'s earnings per share (EPS) for the last quarter?

How many employees does Denali Therapeutics Inc (DNLI). have?

What is Denali Therapeutics Inc (DNLI) market cap?